Matching trials
2,411 results
- Buspirone Therapy for Localized Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Buspirone Therapy for Localized Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01496612).
- Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00800839).
- Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264131).
- BYLieveIndependent statistical analysis of the phase 2 BYLieve trial of alpelisib-based treatment in PIK3CA-mutant, HR+, HER2- advanced breast cancer, including trial design, the primary binary endpoint, planned analysis, statistical interpretation, and safety.
- C_ASCENTIndependent statistical analysis of Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- C-TRAK TNIndependent statistical analysis of C-TRAK TN, a randomized phase 2 trial evaluating ctDNA-guided treatment in early-stage triple-negative breast cancer, including trial design, endpoints, planned statistical methods, and interpretation.
- Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cabozantinib for Adults With Advanced Soft Tissue Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib for Adults With Advanced Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01755195).
- Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04631744).
- Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CADENCEIndependent statistical analysis of the CADENCE phase 2 trial of sotatercept for pulmonary hypertension due to HFpEF, covering its randomized design, pulmonary vascular resistance endpoint, planned analysis, and statistical interpretation.
- Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00258960).
- CAFETERIAIndependent statistical analysis of Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CALECIndependent statistical analysis of Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- CALIPSOIndependent statistical analysis of CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CALMextIndependent statistical analysis of CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext): primary endpoint results, effect estimate with confidence interval, sample-size…
- CAMPBELIndependent statistical analysis of CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cangrelor Ticagrelor Transition Study: Complete Statistical AnalysisIndependent statistical analysis of Cangrelor Ticagrelor Transition Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01766466).
- Cannabidiol in Youth Alcohol Use Disorder: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol in Youth Alcohol Use Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05317546).
- Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00588731).
- Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control: Complete Statistical AnalysisIndependent statistical analysis of Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05477875).
- Cannabis for Spasticity in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Cannabis for Spasticity in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00682929).
- CANTATAIndependent statistical analysis of CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CAO/ARO/AIO-12An independent statistical analysis of the randomized phase 2 CAO/ARO/AIO-12 trial comparing the sequence of induction chemotherapy and preoperative chemoradiotherapy before surgery for locally advanced rectal cancer.
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL: Complete Statistical AnalysisIndependent statistical analysis of Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL: primary endpoint results, effect…
- CAPEIndependent statistical analysis of Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05512962).
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00565370).
- Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00347438).
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…
- Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPRISA 004Independent statistical analysis of CAPRISA 004, a randomized phase 2 study of tenofovir gel versus placebo for prevention of HIV infection, including trial design, endpoint methodology, planned analysis, and statistical interpretation.
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.
- Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00514540).
- Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00447694).
- Cardiometabolic Effects of Pecans as a Snack: Complete Statistical AnalysisIndependent statistical analysis of Cardiometabolic Effects of Pecans as a Snack: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05071807).
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…